Medical College of Wisconsin Affiliated Hospitals Gynecologic Oncology

Topics

• Endometrial and Cervical Cancer Treatments 65
• Ovarian cancer diagnosis and treatment 39
• Cervical Cancer and HPV Research 35
• Genetic factors in colorectal cancer 17
• PARP inhibition in cancer therapy 13
• Uterine Myomas and Treatments 10
• BRCA gene mutations in cancer 7
• MicroRNA in disease regulation 6
• Epigenetics and DNA Methylation 5
• Cancer-related molecular mechanisms research 4
• Ferroptosis and cancer prognosis 4
• Cancer-related Molecular Pathways 3

Most cited

1. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

   The New England journal of medicine · 2023 · 633 citations · Emily Hill

2. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 420 citations · William Bradley

3. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 148 citations · William Bradley

4. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

   The Lancet. Oncology · 2021 · 325 citations · William Bradley

5. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

   Nature medicine · 2025 · 59 citations · Emily Hill

6. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.